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ABSTRACT 
In HIV, highly active anti-retroviral therapy helps patients to regain the immune CD4+ cell count. Among all antiretroviral therapy (ART) 
regimens tenofovir based regimen (TLE; Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV)) has become the most preferred first line 
regimen. Present study aimed to identify the therapeutic levels of drugs in tenofovir based regimen in immunologically stable HIV patients. A 
total of 35 dried blood samples were obtained from HIV patients on TLE treatment visiting ART centre, Mahatma Gandhi Memorial (MGM) 
Hospital, Warangal, Telangana, during September 2017 to March 2018. Patients with good adherence, without history of smoking & alcoholism 
and with CD4+ cell count > 350 cells/mm3 were included. Estimation of drugs was done using pre validated liquid chromatographic method. In 
total of 35 patients, females were accounted for 62.86%. Patients of this study showed high percentage of illiterates (48.57%) and daily labors 
(34.29%). As EFV is a narrow therapeutic index drug it showed significant difference in its plasma therapeutic levels (0.005**) whereas TDF & 
3TC were not. Total of 8.57% and 91.43% patients were showed EFV plasma levels below and above therapeutic levels respectively. Though the 
study patients observed with good immunological status, high percentage of patients identified with toxic levels of EFV concentrations. But 
none of the patients showed any symptoms of toxicity, they are at risk to develop clinical toxicity in future. Present study results suggesting 
dose adjustments and monitoring of drug levels in these patients to avoid early treatment failures and toxicity.  
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1. INTRODUCTION 
Global statistics of UNAIDS 2017 revealed that there were 
36.9 million people are living with HIV (PLHIV) and 21.7 
million people were accessing antiretroviral therapy (ART).1 
In India there were 21.40 lakhs people were living with HIV.2 
Presently 528 ART centers in India providing health services 
to PLHIV.3 The principal impact of HIV infection on the 
immune system is destruction of the CD4+ T lymphocytes4 
and it is only the parameter used to monitor the immune 
status of the HIV infection initiated with ART5 in resource 
limited settings. Highly active antiretroviral therapy 
(HAART) is a triple drug therapy consist two nucleoside or 
nucleotide reverse transcriptase inhibitor backbones with a 
non-nucleoside reverse transcriptase inhibitor or protease 
inhibitor6 recovers the CD4+ T lymphocytes suppressions in 
the HIV infection.7 Among all ART regimens, fixed dose 
combination pill consists of Tenofovir disoproxil fumarate 
(TDF), Lamivudine (3TC) and Efavirenz (EFV) has become 
the preferred first line regimen to initiate the ART in PLHIV.8 
Objective of the present study was originate in view to know 
the levels of a narrow therapeutic index drug (EFV)9 along 
with other two drugs in a fixed dose combination in HIV 
patients with immunologically stable (i.e. CD4+ cell count 
was > 350 cells/mm3) to avoid treatment failure as well as 
toxicity in patients taking this regimen.    
2. METHODOLOGY 
Present study was under taken at ART centre, Mahatma 
Gandhi Memorial (MGM) Hospital, Warangal, Telangana, 
India, duration of the study was 6 months (i.e. September 
2017 to March 2018). A total of forty (n=40) PLHIV on TLE 
treatment for greater than 3 months with no social history of 
alcohol or smoking consumption, with > 98% medication 
adherence and CD4+ count > 350 cells/mm3 were enrolled in 
the study and five patients were exempted from the study 
because of not given consent. Institution review board 
reviewed and approved the protocol. Thirty five (n=35) 
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dried blood samples from patients with given consent were 
obtained at the time of their regular review visit after 8 to 14 
hours of post dosing.9 Three antiretroviral drugs of (TDF, 
3TC and EFV) TLE regimen were estimated using pre 
validated liquid chromatographic method.6 Results were 
represented in the form of mean±SD.        
3. RESULTS AND DISCUSSION 
3.1. Study patient’s characteristics 
Table 1 shows the characteristics of total 35 study patient’s 
data. Out of 35 patients, 37.14% (n=13) were males and 
62.86% (n=22) were females. Mean age of overall patients 
was observed as 41±10.04 (26 – 65) years. Gender 
distribution of these patients according to age was shown in 
Figure 1 and most of them were observed in the age group of 
30 – 50 years, where it was 15 – 40 years in a surveillance 
study conducted by UNAIDS in sub-Saharan Africa.10 Body 
mass index (BMI kg/m2) of the patients showed 94.29% 
were underweight and only 5.71% patients were observed 
with normal BMI. In present study the most predominant 
route of HIV infection transmission was noticed as 
heterosexual route which was similar to the reports of Shen 
et al., (2016);11 Lakhashe et al., (2008);12 Kumarasamy et al., 
(2005);13 Godbole et al., (2014).14 The highest percentage of 
patients of this study was illiterates (48.57%) and daily 
labors (34.29%) these results were in parallel to the earlier 
studies Obiako et al., 201215 & Sood et al., 2017.16 
 
Table 1: Characteristics of study patients. 
Parameter Number of patients Percentage (%) 
Gender   
Male 13 37.14 
Female 22 62.86 
Age in years Mean±SD  
Males 45±9.26 
0.19 (ns) 
Females 38.64±9.93 
Body Weight in Kgs Mean±SD  
≤ 40 09 25.71 
40 – 60  22 62.86 
≥ 60 04 11.43 
BMI (kg/m2)   
Underweight (< 18.5) 33 94.29 
Normal weight (18.5-24.9) 02 5.71 
Over weight and obese - - 
Occupation Number of patients Percentage (%) 
Daily labor 12 34.29 
Private employee 06 17.14 
Agriculture 06 17.14 
Home maker 03 8.57 
Without occupation 08 22.86 
Mode of transmission  
Hetero sexual 29 82.86 
Migrant  02 5.71 
Mother to child  04 11.43 
Educational status 
Illiterates  17 48.57 
Primary  06 17.14 
Secondary 08 22.86 
College &above 04 11.43 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Gender distribution of study patients according to age. 
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3.2. Basic clinical data and plasma drug levels 
Basic clinical data of the study patients were tabulated in 
Table 2. These patients mean duration of the disease in 
months was found to be 63.63±42.05 (ranged 7 – 140 
months) (males: 59.23±39.92; females: 66.23±43.96). The 
mean duration of treatment (TLE) received by the time of 
sample collection was 38.06±24.02 (6 to 88) months (males: 
42.45±25.85 and females: 30.62±19.22). The overall mean 
value of recent CD4+ count of was observed as 
515.91±130.97 cells/mm3, with 358 to 843 cells/mm3 range.  
 
Table 2: Basic clinical data of the study patients. 
Parameter 
Values Mean±SD 
Male Female 
Duration of the disease in months 59.23±39.92 66.23±43.96 
Duration of treatment on TLE in months 42.45±25.85 30.62±19.22 
Recent CD4+ count in cells/mm3 501.39±153.77 524.5±118.54 
 
Efavirenz is a narrow therapeutic indexed drug in TLE 
regimen and its therapeutic level is 1 – 4 mg/L.9,17,18 As 
depicted in Table 3 in present study estimated plasma levels 
of EFV, TDF and 3TC were showed only 8.57% of patients 
with EFV concentrations within therapeutic level and 
91.43% of patients with EFV concentrations above 
therapeutic level with significant difference (0.005**) in 
between two therapeutic level groups. On the other hand the 
overall plasma concentrations of the TDF (p=0.68) and 3TC 
(p=0.06) were within the limits i.e. Cmin/Cmax for TDF and 
3TC were 0.06/0.33 mg/L19,20 and 0.04/2.0 mg/L21,22 
respectively with no significant difference between two 
groups.
 
Table 3: Plasma levels of three drugs at different therapeutic levels of EFV. 
Patients 
(n=35) 
Values Mean±SD mg/L  
EFV conc. 
(mg/L) 
P
 v
a
lu
e
 
TDF conc. 
(mg/L) 
P
 v
a
lu
e
 
3TC conc. 
(mg/L) 
P
 v
a
lu
e
 
EFV Within TL (n=03; 8.57%)  3.25±0.37 
0
.0
0
5
*
* 
0.16±0.1 
0
.6
8
 
(n
s)
 0.09±0.04 
0
.0
6
 
(n
s)
 
EFV above TL (n=32; 91.43%) 12.63±11.57 0.14±0.09 0.33±0.02 
 
From the earlier study of Manosuthi et al., (2009)23 it was 
observed that body weight > 60 Kgs will result in low 
therapeutic levels of plasma EFV. But in present study only 
four patients body weight was > 60 Kgs with mean plasma 
EFV level of 9.03±2.70 mg/L i.e. above therapeutic level. As 
shown in Figure 2 patients body weight has no significant 
(p=0.34) affect on plasma EFV levels and these results 
supporting the results of Burger et al., (2005)17 and 
Luetkemeyer et al., (2013)18 where there results proved 
body weight has no affect on plasma EFV levels. 
Demographic data of the patients showed 94.29% of the 
patients were under weight; as reported by Poeta et al., 
(2011)24 i.e., BMI is associated significantly and inversely 
to the EFV concentrations, BMI < 18.5 kg/m2 
(underweight) might be the reason for higher therapeutic 
levels of EFV in this study patients too. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: Effect of Bodyweight on plasma EFV concentration.  
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Table 4 shows the patient’s history of past ART regimen and 
its effect on plasma EFV levels. A total of 46.88% patients 
underwent regimen change before to TLE regimen and 
ZLN+TLN was the regimen received by most of the patients. 
There was a significant (p=0.02*) difference of plasma EFV 
levels were observed in between past HAART history to no 
history groups. 
 
Table 4: Effect of medication switches on EFV concentrations 
Medication Switch 
EFV mg/L 
(Mean±SD) 
ZLN (n=02) 6.71±0.14 
SLN+TLN (n=03) 13.99±10.84 
ZLN+TLN (n=06) 4.43±0.64 
SLE+SLN+TLN (n=02) 7.59±0.07 
SLN+TLN+ZLN (n=02) 7.58±0.15 
Past HAART history (n=15; 46.88%) p value 
0.02* No history (n=17; 53.13%) 
 
Alike, correlation between medication switch to plasma EFV 
levels, there was a significant effect (p=0.021*) of medication 
switch on CD4+ cell count was noticed (Figure 3). Increased 
rate of CD4+ cell count might be as result of multiple HAART 
regimen exposures over a period of time this strengthen the 
results of Trotta et al., (2010)7 and Bisson et al., (2006)25 that 
multiple drug regimen exposure increase the CD4+ cell count.
 
 
 
4. INTERPRETATION AND CONCLUSION 
Though the patients of this study observed with good 
immunological status (i.e. > 350 cells/mm3), 91.43% 
patients identified with toxic levels of EFV concentrations 
(above therapeutic level). None of the patient showed any 
symptoms of toxicity they might be in subclinical toxicity 
stage at the time of study but they are at risk to develop 
clinical toxicity in future. These patients need dose 
adjustment to lower dose with frequent monitoring of 
clinical and immunological status to avoid toxicity related 
complications in future. Significant difference (p value – 
0.02* ) of EFV concentration between groups of past and no 
past HAART history suggesting the monitoring of narrow 
therapeutic index drug in patients undertake medical 
switches is necessary to avoid unnecessary regimen 
switches where limited number of HAART options are 
presented.  
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